Jasmin Emmenegger

Roche (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

2h-index26citations22works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(22), Computational Drug Discovery Methods(17), Protein Kinase Regulation and GTPase Signaling(10), Synthesis and biological activity(6), Synthesis of Tetrazole Derivatives(4)

Publications22 total

Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Jürgen Wichmann(22), Martin Kornacker(22), Jan Eckmann(22), Gabriel Schnetzler(22), James R. Bischoff(22), Piergiorgio Pettazzoni(22), Cornelia Handl(20), Caroline Rynn(15), Thomas Friess(15), Jeannine Petrig-Schaffland(15), Frank Herting(15), Nicolas Frances(15), Daniel Hunziker(15), Daniela Krummenacher(15), Dominik Rüttinger(15), Alison Ribeiro(15), Marina Bacac(15), Alessandro Brigo(15), David S. Hewings(15), Reinhard Dummer(15)